

## Gavi 2016-2020 Strategic Indicators Baselines and Targets

	Indicator	2015 Baseline	2020 Target	Supplemental/detailed baseline data
Aspiration 2020	<b>MA1</b> Under five mortality rate	62 deaths per 1000 live births	10% reduction from 2015 baseline	
	<b>MA2</b> Number of future deaths averted	0	5-6 million	
	<b>MA3</b> Future DALYs averted	0	250 million	
	<b>MA4</b> Number of unique children immunised	N/A	300 million	
	<b>MA5</b> Vaccines sustained after transition	N/A	100%	
Disease Dashboard	<b>D1</b> Hepatitis B: Number of Gavi 73 countries that have less than 2% hepatitis B surface antigen (HBsAg) prevalence among children less than 5 years of age among countries with surveys meeting inclusion criteria	83%	N/A – tracked over time	5 countries out of 6 reporting at 2015 baseline
	<b>D2</b> Rotavirus: Median proportion (and interquartile range) of acute gastroenteritis hospitalisations positive for rotavirus among children less than one year of age among Gavi countries with any site meeting inclusion criteria	24.2% (19.1%, 41.6%)	N/A – tracked over time	25 countries reporting at 2015 baseline
	<b>D3</b> Measles: Number of Gavi countries reporting an annual measles incidence of less than 5 cases per million population	50%	N/A – tracked over time	35 countries out of 70 reporting at 2015 baseline
Strategic goal 1	<b>S1.1</b> Reach of routine: penta3 and MCV1 coverage	Penta3: 79%; MCV1: 78%	+5 PP for Penta3 and MCV1 from 2016-2020	Baseline data updated based on July 2018 WUENIC release
	<b>S1.2</b> Breadth of protection: average coverage across all Gavi supported vaccines	30%	+32 PP from 2015 baseline	Baseline data updated based on July 2018 WUENIC release
	<b>S1.3</b> Equity by geography: Average proportion of districts with DTP3 coverage ≥80%, across all Gavi68 countries	80%	+10 PP from 2015 baseline	Baseline and target set based on revised indicator definition approved by the Gavi Board in June 2018

Strategic goal 2	<b>S1.4</b> Equity by wealth: Average (unweighted) difference in coverage of third dose pentavalent vaccine between the richest and poorest quintiles	19%	16% (-3 PP from 2015 baseline)	Baseline and target set based on revised indicator definition approved by the Gavi Board in June 2018
	<b>S1.5</b> Equity by gender: Average (unweighted) difference in coverage of third dose of pentavalent vaccine between children whose mothers/female caretakers have received no education and children whose mothers/female caretakers have completed secondary education or higher	19%	15% (-4 PP from 2015 baseline)	Baseline and target set based on revised indicator definition approved by the Gavi Board in June 2018
	<b>S2.1</b> Effective vaccine management: Average of country composite score on last completed Effective Vaccine Management (EVM) assessment	67%	72%	Baseline and target set based on revised indicator definition approved by the Gavi Board in November 2018
	<b>S2.2</b> Data quality/consistency: % countries with survey in last 5 years and <10 percentage point difference between national administrative coverage and point estimate from survey	45%	+10 PP from 2015 baseline	
	<b>S2.3</b> Access, demand and service delivery: coverage with first dose of pentavalent vaccine and drop out between first and third dose	Penta1:86%; Drop-out: 8%	Penta1: +4 PP; Drop-out: -3 PP from 2015 baseline	Baseline data updated based on July 2018 WUENIC release
	<b>S2.4</b> Integration: % countries meeting benchmark for integrated service delivery	26% (18/68 countries)	+10 PP from 2016-2020	Criterion 1: 67%, Criterion 2: 65%

	<b>S2.5</b> Civil society engagement: % Gavi-supported countries meeting benchmarks for civil society engagement in national immunisation programmes to improve coverage and equity	NA	43%	2020 target set based on revised indicator definition approved by the Gavi Board in November 2018.
Strategic goal 3	<b>S3.1</b> Co-financing: % countries fulfilling commitments	85%	100%	
	<b>S3.2</b> Country investment in routine immunisation per child: % countries increasing investment	N/A	100%	2020 target represents % of countries increasing investment relative 2015 baseline
	<b>S3.3</b> Programmatic sustainability: % countries on track for successful transition	63%	75%	
	<b>S3.4</b> Institutional capacity: Average of country composite score for national decision making, programme management and monitoring	2.4 out of 4.0	2.7 out of 4.0	Baseline and target set based on revised indicator definition approved by the Gavi Board in November 2018
Strategic goal 4	<b>S4.1</b> Sufficient and uninterrupted supply: # vaccine markets where supply meets Gavi demand	7 out of 11	11 out of 11 in 2020	
	<b>S4.2</b> Reduction in price: price of fully vaccinating child with pentavalent, pneumococcal and rotavirus vaccines	\$20	Not published due to commercial sensitivity	

	<b>S4.3</b> Innovation: # vaccines with improved characteristics procured by Gavi	N/A	10 in 2020	
	<b>S4.4</b> Healthy market dynamics: # vaccine markets with moderate or high healthy market dynamics	1 out of 11	6 out of 11 in 2020	